PASG
Passage Bio, Inc.
Biotechnology
Market Cap$18M
5Y Perf.-99.0%
Build Your Comparison
Side-by-side financial analysisPASG
RARE
Try popular comparisons:
Stock Comparison
PASG vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.70B
5Y Perf.-64.9%
PASG vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  PASG |  RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $18M | $2.70B |
| Revenue (TTM) | $0.00 | $669M |
| Net Income (TTM) | $-38M | $-609M |
| Gross Margin | — | 83.6% |
| Operating Margin | — | -83.9% |
| Total Debt | $24M | $1.28B |
| Cash & Equiv. | $46M | $434M |
PASG vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PASG
RARE
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Passage Bio, Inc. (PASG) | 100 | 1.0 | -99.0% |
| Ultragenyx Pharmace… (RARE) | 100 | 35.1 | -64.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PASG vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RARE leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Passage Bio, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇RARE emerged as the overall leader. Track its performance:
PASG
Passage Bio, Inc.
The Growth Play
PASG is the clearest fit if your priority is growth exposure.
- EPS growth 33.1%
- 39.6% revenue growth vs RARE's 20.1%
- 3.7% margin vs RARE's -91.0%
Best for: growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Income Pick
RARE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.37
- -49.7% 10Y total return vs PASG's -98.7%
- Lower volatility, beta 1.37, current ratio 2.48x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  PASG | 39.6% revenue growth vs RARE's 20.1% |
| Quality / Margins | PASG | 3.7% margin vs RARE's -91.0% |
| Stability / Safety |  RARE | Beta 1.37 vs PASG's 3.30 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RARE | -26.5% vs PASG's -28.4% |
| Efficiency (ROA) | RARE | -45.8% ROA vs PASG's -59.8%, ROIC -89.4% vs -141.9% |
PASG vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
PASG vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRARELAGGINGPASG
PASGPassage Bio, Inc.
1leads
RAREUltragenyx Pharmaceut…
4leads
6 Total Categories
CATEGORYLEADERvs PASGMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PASG1/1
Valuation MetricsMultiples, price ratios, and targets
RARE1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RARE4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
RARE6/6
Risk & VolatilityBeta, volatility, and downside exposure
RARE2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PASG leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RARE and PASG operate at a comparable scale, with $669M and $0 in trailing revenue.
| Metric | PASGPassage Bio, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $669M |
| EBITDAEarnings before interest/tax | -$41M | -$536M |
| Net IncomeAfter-tax profit | -$38M | -$609M |
| Free Cash FlowCash after capex | -$31M | -$487M |
| Gross MarginGross profit ÷ Revenue | — | +83.6% |
| Operating MarginEBIT ÷ Revenue | — | -83.9% |
| Net MarginNet income ÷ Revenue | — | -91.0% |
| FCF MarginFCF ÷ Revenue | — | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +52.4% | -17.2% |
PASG leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
RARE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | PASGPassage Bio, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $18M | $2.7B |
| Enterprise ValueMkt cap + debt − cash | -$4M | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.39x | -4.71x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 4.01x |
| Price / BookPrice ÷ Book value/share | 0.95x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
RARE leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
RARE leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
PASG delivers a -150.9% return on equity — every $100 of shareholder capital generates $-151 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), RARE scores 4/9 vs PASG's 1/9, reflecting mixed financial health.
| Metric | PASGPassage Bio, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -150.9% | -6.1% |
| ROA (TTM)Return on assets | -59.8% | -45.8% |
| ROICReturn on invested capital | -141.9% | -89.4% |
| ROCEReturn on capital employed | -70.6% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 1.28x | — |
| Net DebtTotal debt minus cash | -$22M | $842M |
| Cash & Equiv.Liquid assets | $46M | $434M |
| Total DebtShort + long-term debt | $24M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | — | -14.49x |
RARE leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
RARE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RARE five years ago would be worth $2,891 today (with dividends reinvested), compared to $195 for PASG. Over the past 12 months, RARE leads with a -26.5% total return vs PASG's -28.4%. The 3-year compound annual growth rate (CAGR) favors RARE at -18.2% vs PASG's -32.9% — a key indicator of consistent wealth creation.
| Metric | PASGPassage Bio, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | -52.2% | +16.3% |
| 1-Year ReturnPast 12 months | -28.4% | -26.5% |
| 3-Year ReturnCumulative with dividends | -69.8% | -45.3% |
| 5-Year ReturnCumulative with dividends | -98.1% | -71.1% |
| 10-Year ReturnCumulative with dividends | -98.7% | -49.7% |
| CAGR (3Y)Annualised 3-year return | -32.9% | -18.2% |
RARE leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
RARE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RARE is the less volatile stock with a 1.37 beta — it tends to amplify market swings less than PASG's 3.30 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RARE currently trades 64.8% from its 52-week high vs PASG's 28.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PASGPassage Bio, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.30x | 1.37x |
| 52-Week HighHighest price in past year | $20.00 | $42.37 |
| 52-Week LowLowest price in past year | $3.94 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +28.0% | +64.8% |
| RSI (14)Momentum oscillator 0–100 | 44.6 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 86K | 1.6M |
RARE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PASGPassage Bio, Inc. | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $48.36 |
| # AnalystsCovering analysts | — | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RARE leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). PASG leads in 1 (Income & Cash Flow).
Best OverallUltragenyx Pharmaceutical I… (RARE)Leads 4 of 6 categories
Loading custom metrics...
PASG vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PASG or RARE a better buy right now?
Analysts rate Ultragenyx Pharmaceutical Inc.
(RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PASG or RARE?
Over the past 5 years, Ultragenyx Pharmaceutical Inc.
(RARE) delivered a total return of -71. 1%, compared to -98. 1% for Passage Bio, Inc. (PASG). Over 10 years, the gap is even starker: RARE returned -49. 7% versus PASG's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PASG or RARE?
By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.
(RARE) is the lower-risk stock at 1. 37β versus Passage Bio, Inc. 's 3. 30β — meaning PASG is approximately 141% more volatile than RARE relative to the S&P 500.
04Which is growing faster — PASG or RARE?
On earnings-per-share growth, the picture is similar: Passage Bio, Inc.
grew EPS 33. 1% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PASG or RARE?
Passage Bio, Inc.
(PASG) is the more profitable company, earning 0. 0% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PASG leads at 0. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PASG or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PASG or RARE better for a retirement portfolio?
For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Passage Bio, Inc. (PASG) carries a higher beta of 3. 30 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RARE: -49. 7%, PASG: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PASG and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PASG is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.